Maxime Dely Suggested New Algorithm to Choose Blood Donor
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“What if blood transfusion was… Tinder?
Today, algorithms shape almost everything: the music we listen to, the routes we take… and even the people we meet.
So why not push the analogy all the way to blood transfusion?
Just like on Tinder, everything starts with a matchmaking process: on one side a donor, on the other a patient. The goal? Finding the perfect match.
And in both cases… you’d rather avoid a bad date.
Except in medicine, the algorithm is far more demanding:
ABO blood group typing,
Rh factor,
Crossmatching,
Antibody screening,
Verification of immunological compatibility…
A scientific “swipe” ensuring no immune reaction ruins the meeting between these two profiles.
When everything aligns, we get the key moment:
It’s a match!
No pink animation, but a compatibility that can stabilize, treat, or save a life.
In the end, Tinder or transfusion—it’s the same logic:
- Find the right connection,
- Avoid incompatibilities,
- Make sure the match actually works.
And maybe the most meaningful match of all… is the one created when you donate blood.”
Never miss an update from Hemostasis Today.
-
Apr 23, 2026, 22:46Gloria Duah: Not All ‘O Negative’ Blood Is Safe for Every Patient
-
Apr 23, 2026, 22:46Luke McLaughlin: Is Haemophilia a disability? – Vote or Share
-
Apr 23, 2026, 22:44Sonia Wolf: On My Way Back From a Very Invigorating BSH
-
Apr 23, 2026, 22:43Maximo Agustin Schiavone: ‘The Lower the Better’ Is Not a Physiological Principle
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
-
Apr 23, 2026, 17:57Shalini R: Not All Blood Thinners Are the Same
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran: Navigating the Clinical Complexity of Combined Red Cell Disorders
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved
-
Apr 23, 2026, 17:19Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism